Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

Similar articles for PubMed (Select 15920519)

1.

Mining for regulatory programs in the cancer transcriptome.

Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM.

Nat Genet. 2005 Jun;37(6):579-83.

PMID:
15920519
2.

Gene expression phenotypic models that predict the activity of oncogenic pathways.

Huang E, Ishida S, Pittman J, Dressman H, Bild A, Kloos M, D'Amico M, Pestell RG, West M, Nevins JR.

Nat Genet. 2003 Jun;34(2):226-30.

PMID:
12754511
3.

A novel factor distinct from E2F mediates C-MYC promoter activation through its E2F element during exit from quiescence.

Alvaro-Blanco J, Martínez-Gac L, Calonge E, Rodríguez-Martínez M, Molina-Privado I, Redondo JM, Alcamí J, Flemington EK, Campanero MR.

Carcinogenesis. 2009 Mar;30(3):440-8. doi: 10.1093/carcin/bgp002. Epub 2009 Jan 6.

4.
6.
7.

Graph-based identification of cancer signaling pathways from published gene expression signatures using PubLiME.

Finocchiaro G, Mancuso FM, Cittaro D, Muller H.

Nucleic Acids Res. 2007;35(7):2343-55. Epub 2007 Mar 27.

8.

Sizing up miRNAs as cancer genes.

Caldas C, Brenton JD.

Nat Med. 2005 Jul;11(7):712-4. No abstract available.

PMID:
16015356
9.

Transcription Regulatory Regions Database (TRRD): its status in 2002.

Kolchanov NA, Ignatieva EV, Ananko EA, Podkolodnaya OA, Stepanenko IL, Merkulova TI, Pozdnyakov MA, Podkolodny NL, Naumochkin AN, Romashchenko AG.

Nucleic Acids Res. 2002 Jan 1;30(1):312-7.

11.

Transcriptional regulation of the 5'-flanking region of the human transcription factor Sp3 gene by NF-1, c-Myb, B-Myb, AP-1 and E2F.

Tapias A, Ciudad CJ, Noé V.

Biochim Biophys Acta. 2008 May;1779(5):318-29. doi: 10.1016/j.bbagrm.2008.02.006. Epub 2008 Mar 10.

PMID:
18342022
12.

Mapping of genetic and epigenetic regulatory networks using microarrays.

van Steensel B.

Nat Genet. 2005 Jun;37 Suppl:S18-24. Review.

PMID:
15920525
13.
14.

A new E6/P63 pathway, together with a strong E7/E2F mitotic pathway, modulates the transcriptome in cervical cancer cells.

Teissier S, Ben Khalifa Y, Mori M, Pautier P, Desaintes C, Thierry F.

J Virol. 2007 Sep;81(17):9368-76. Epub 2007 Jun 20.

15.

CRE-palindrome oligonucleotide as a transcription factor decoy and an inhibitor of tumor growth.

Cho-Chung YS.

Antisense Nucleic Acid Drug Dev. 1998 Apr;8(2):167-70. Review. No abstract available.

PMID:
9593058
16.

Transcriptional regulation of the mouse PNRC2 promoter by the nuclear factor Y (NFY) and E2F1.

Zhou D, Masri S, Ye JJ, Chen S.

Gene. 2005 Nov 21;361:89-100. Epub 2005 Sep 21.

PMID:
16181749
17.

TCR pathway involves ICBP90 gene down-regulation via E2F binding sites.

Abbady AQ, Bronner C, Bathami K, Muller CD, Jeanblanc M, Mathieu E, Klein JP, Candolfi E, Mousli M.

Biochem Pharmacol. 2005 Aug 15;70(4):570-9.

PMID:
15964557
18.

Evolutionary conservation of zinc finger transcription factor binding sites in promoters of genes co-expressed with WT1 in prostate cancer.

Eisermann K, Tandon S, Bazarov A, Brett A, Fraizer G, Piontkivska H.

BMC Genomics. 2008 Jul 16;9:337. doi: 10.1186/1471-2164-9-337.

19.

Lap2alpha expression is controlled by E2F and deregulated in various human tumors.

Parise P, Finocchiaro G, Masciadri B, Quarto M, Francois S, Mancuso F, Muller H.

Cell Cycle. 2006 Jun;5(12):1331-41. Epub 2006 Jun 15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk